Evidence map›Paper›PMID 37581388›Full record

Observational studyJournal of the American Heart Association2023

Real-World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome.

Mustafa Yildirim, Matthias Mueller-Hennessen, Barbara Ruth Milles, Moritz Biener, Hauke Hund, Norbert Frey, Evangelos Giannitsis, Christian Salbach

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Type 1 and type 2 NSTEMI in atrial fibrillation: insights from the HERA-FIB registry.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Observational
  2. Review
  3. Dual antiplatelet pre-treatment with aspirin and ticagrelor in ACS patients undergoing unplanned aortocoronary bypass surgery.Clinical research in cardiology : official journal of the German Cardiac Society · 2025
    Observational
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Mustafa YildirimDepartment of Internal Medicine III, Cardiology University Hospital of Heidelberg Heidelberg Germany.
Matthias Mueller-HennessenDepartment of Internal Medicine III, Cardiology University Hospital of Heidelberg Heidelberg Germany.
Barbara Ruth MillesDepartment of Internal Medicine III, Cardiology University Hospital of Heidelberg Heidelberg Germany.
Moritz BienerDepartment of Internal Medicine III, Cardiology University Hospital of Heidelberg Heidelberg Germany.ORCID 0000-0001-6763-6538
Hauke HundDepartment of Internal Medicine III, Cardiology University Hospital of Heidelberg Heidelberg Germany.
Norbert FreyDepartment of Internal Medicine III, Cardiology University Hospital of Heidelberg Heidelberg Germany.
Evangelos GiannitsisDepartment of Internal Medicine III, Cardiology University Hospital of Heidelberg Heidelberg Germany.
Christian SalbachDepartment of Internal Medicine III, Cardiology University Hospital of Heidelberg Heidelberg Germany.ORCID 0000-0002-1799-545X
Heidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Management of patients with non-ST-segment-elevation acute coronary syndrome (NSTE-ACS) is based on 2020 European Society of Cardiology guidelines, which recommend the preferential use of prasugrel over ticagrelor. Because the selection of the respective P

Indexed as

Acute Coronary SyndromeMyocardial InfarctionPercutaneous Coronary InterventionST Elevation Myocardial InfarctionHumansPlatelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsRetrospective StudiesTicagrelorTreatment OutcomePlatelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsTicagreloracute coronary syndromeeligibilitylabel useprasugrelticagrelor

Identifiers

PMID37581388
PMCPMC10492934
OpenAlexW4385724568

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.